Theravance Biopharma (NASDAQ:TBPH) Lowered to “Buy” Rating by Wall Street Zen

Theravance Biopharma (NASDAQ:TBPH) was downgraded by investment analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Monday.

Other research analysts have also issued research reports about the company. Weiss Ratings raised Theravance Biopharma from a “hold (c)” rating to a “buy (b-)” rating in a research report on Tuesday, March 24th. TD Cowen increased their target price on Theravance Biopharma from $13.00 to $15.00 and gave the stock a “hold” rating in a research note on Monday, March 23rd. Oppenheimer downgraded Theravance Biopharma from an “outperform” rating to a “market perform” rating in a report on Thursday, March 5th. HC Wainwright lifted their price target on Theravance Biopharma from $20.00 to $27.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Finally, B. Riley Financial reiterated a “neutral” rating and issued a $14.00 price target (down from $28.00) on shares of Theravance Biopharma in a research note on Wednesday, March 4th. Two investment analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $21.33.

Theravance Biopharma Stock Performance

Shares of NASDAQ TBPH opened at $16.02 on Monday. Theravance Biopharma has a fifty-two week low of $7.90 and a fifty-two week high of $21.03. The company has a 50 day simple moving average of $17.05 and a two-hundred day simple moving average of $16.99. The company has a market capitalization of $824.87 million, a price-to-earnings ratio of 7.89 and a beta of 0.17.

Insider Buying and Selling at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 31,067 shares of the company’s stock in a transaction on Monday, March 16th. The stock was sold at an average price of $13.96, for a total transaction of $433,695.32. Following the transaction, the senior vice president directly owned 232,699 shares of the company’s stock, valued at $3,248,478.04. This represents a 11.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 6.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Theravance Biopharma

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Baader Bank Aktiengesellschaft purchased a new position in shares of Theravance Biopharma during the third quarter valued at approximately $781,000. Hillsdale Investment Management Inc. purchased a new stake in Theravance Biopharma in the third quarter worth approximately $4,536,000. JPMorgan Chase & Co. grew its position in Theravance Biopharma by 78.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 213,104 shares of the biopharmaceutical company’s stock worth $3,111,000 after purchasing an additional 93,591 shares during the period. Inspire Investing LLC purchased a new stake in Theravance Biopharma during the 3rd quarter valued at $1,074,000. Finally, Assenagon Asset Management S.A. raised its stake in Theravance Biopharma by 1,629.4% during the 3rd quarter. Assenagon Asset Management S.A. now owns 414,715 shares of the biopharmaceutical company’s stock valued at $6,055,000 after buying an additional 390,735 shares during the last quarter. Institutional investors own 99.10% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.